Strategies for clinical dose optimization of T cell-engaging therapies in oncology
Innovative approaches in the design of T cell-engaging (TCE) molecules are ushering in a new wave of promising immunotherapies for the treatment of cancer. Their mechanism of action, which generates an in trans interaction to create a synthetic immune synapse, leads to complex and interconnected rel...
Saved in:
| Main Authors: | Kathryn Ball, Simon J Dovedi, Pavan Vajjah, Alex Phipps |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2023-12-01
|
| Series: | mAbs |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/19420862.2023.2181016 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Population Pharmacokinetic and Exposure–Response Analyses for Ponatinib in the Phase 3 PhALLCON Study
by: Michael J. Hanley, et al.
Published: (2025-03-01) -
Bispecific killer engager for targeted depletion of PD-1 positive lymphocytes: A new avenue for autoimmune disease treatment
by: Lauren C. Naatz, et al.
Published: (2025-03-01) -
Exploring molecular determinants and pharmacokinetic properties of IgG1-scFv bispecific antibodies
by: Kristina M.J. Aertker, et al.
Published: (2024-12-01) -
Six events that shaped antibody approvals in oncology
by: Suman Paul, et al.
Published: (2025-02-01) -
Model-Informed Precision Dosing of Levamlodipine Besylate in Smoking Patients
by: Li G, et al.
Published: (2025-04-01)